Patent ID: 8883808

Claim:
A pharmaceutical composition comprising: (a) (i) a therapeutically effective amount of a 5-HT7 receptor antagonist, wherein said 5-HT7 receptor antagonist is selected from the group consisting of: (R)-3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol; (R)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzene sulfonamide; R-(+)-1-(toluene-3-sulfonyl)-2[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine; LY-215840; 2a-[4-4-phenyl-1,2,3,6-tetrahydropyridyl])-2a,3,4,5-tetrahydrobenzo[ed]-indol[(iH)-1; Ensaculin; S 23751; Zopetine; SB248709; BTS 79018; and 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; and (ii) a therapeutically effective amount of a serotonin reuptake inhibitor, said amounts together providing an effective combined amount; and (b) a pharmaceutically acceptable excipient.